Vnitr Lek 2019, 65(2):126-130 | DOI: 10.36290/vnl.2019.025

Treatment of antibody immunodeficiency

Jiří Litzman
Ústav klinické imunologie a alergologie LF MU a FN u sv. Anny v Brně

The basis of treatment of patients with hypogammaglobulinemia, primary or secondary, is immunoglobulin replacement. Current immunoglobulin derivates contain highly purified IgG from healthy human donors. Intravenous or subcutaneous route are almost exclusively used at present. The treatment must be individualized. Adequate doses of immunoglobulin derivates must be administered to avoid frequent and severe infections of the respiratory tract. Antibiotic prophylaxis may be alternative and complementary treatment to immunoglobulin substitution.

Keywords: antibiotic prophylaxis; antibody immunodeficiency; immunoglobulin replacement treatment

Received: July 1, 2018; Accepted: November 26, 2018; Published: February 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Litzman J. Treatment of antibody immunodeficiency. Vnitr Lek. 2019;65(2):126-130. doi: 10.36290/vnl.2019.025.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dhalla F, Misbah SA. Secondary antibody deficiencies. Curr Opin Allergy Clin Immunol 2015; 15(6): 505-513. Dostupné z DOI: <http://dx.doi.org/10.1097/ACI.0000000000000215>. Go to original source... Go to PubMed...
    2. Bonilla FA, Barlan I, Chapel H et al. International Consensus Document (ICON): Common Variable Immunodeficiency Disorders. J Allergy Clin Immunol Pract 2016; 4(1): 38-59. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaip.2015.07.025>. Go to original source... Go to PubMed...
    3. Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol 2009; 145(6): 709-727. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365-2141.2009.07669.x>. Go to original source... Go to PubMed...
    4. Gathmann B, Mahlaoui N, Gérard L et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol 2014; 134(1): 116-126. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2013.12.1077>. Go to original source... Go to PubMed...
    5. Ameratunga R, Woon ST, Gillis D et al. New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin. Clin Exp Immunol 2013; 174(2): 203-211. Dostupné z DOI: <http://dx.doi.org/10.1111/cei.12178>. Go to original source... Go to PubMed...
    6. Jolles S, Chapel H, Litzman J. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. Clin Exp Immunol 2017; 188(3): 333-341. Dostupné z DOI: <http://dx.doi.org/10.1111/cei.12915>. Go to original source... Go to PubMed...
    7. [Výbor České společnosti alergologie a klinické imunologie, Pracovní skupina pro primární imunodeficience]. Návrh standardu imunoglobulinové léčby nemocných s protilátkovými imunodeficienciemi. Alergie 2016; 18(1): 29-30.
    8. Hoffman TW, van Kessel DA, van Velzen-Blad H et al. Antibody replacement therapy in primary antibody deficiencies and iatrogenic hypogammaglobulinemia. Expert Rev Clin Immunol 2015; 11(8): 921-933. Dostupné z DOI: <http://dx.doi.org/10.1586/1744666X.2015.1049599>. Go to original source... Go to PubMed...
    9. Králíčková P. Současné formy imunoglobulinové substituční léčby. Alergie 2016; 18(2): 129-132.
    10. Abolhassani H, Asgardoon MH, Rezaei N et al. Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient? Expert Rev Clin Immunol 2015; 11(11): 1229-1243. Dostupné z DOI: <http://dx.doi.org/10.1586/1744666X.2015.1079485>. Go to original source... Go to PubMed...
    11. Maarschalk-Ellerbroek LJ, Hoepelman IM, Ellerbroek PM. Immunoglobulin treatment in primary antibody deficiency. Int J Antimicrob Agents 2011; 37(5): 396-404. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijantimicag.2010.11.027>. Go to original source... Go to PubMed...
    12. Šutová I, Chovancová Z, Litzman J. Nežádoucí účinky imunoglobulinové léčby. Alergie 2018; 20(2): 123-128.
    13. Berger M, Jolles S, Orange JS et al. Bioavailability of IgG administered by the subcutaneous route. J Clin Immunol 2013; 33(5): 984-990. Dostupné z DOI: <http://dx.doi.org/10.1007/s10875-013-9876-3>. Go to original source... Go to PubMed...
    14. Hoffmann F, Grimbacher B, Thiel J et al. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Eur J Med Res 2010; 15(6): 238-245. Go to original source... Go to PubMed...
    15. Shapiro RS. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis. Ann Allergy Asthma Immunol 2013; 111(1): 51-55. Dostupné z DOI: <http://dx.doi.org/10.1016/j.anai.2013.04.015>. Go to original source... Go to PubMed...
    16. Milota T, Šedivá A. Nové možnosti a perspektivy imunoglobulinové terapie. Alergie 2016; 18(4): 248-252.
    17. Wasserman RL, Melamed I, Stein MR et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol 2012; 130(4): 951-957. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2012.06.021>. Go to original source... Go to PubMed...
    18. Litzman J. Návrh standardu domácí imunoglobulinové léčby u pacientů s protilátkovým imunodeficitem. Alergie 2006; 8(1): 61-62.
    19. Fasth A, Nyström J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol 2008; 28(4): 370-378. Dostupné z DOI: <http://dx.doi.org/10.1007/s10875-008-9180-9>. Go to original source... Go to PubMed...
    20. Kittner JM, Grimbacher B, Wulff W et al. Patients' attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol 2006; 26(4): 400-405. Dostupné z DOI: <http://dx.doi.org/10.1007/s10875-006-9031-5>. Go to original source... Go to PubMed...
    21. Healey C, Chapel H. Intravenous immunoglobulin and hepatitis C virus: the British episode. Clin Ther 1996; 18: (Suppl B): 93-95. Go to original source... Go to PubMed...
    22. Gelfand EW, Ochs HD, Shearer WT. Controversies in IgG replacement therapy in patients with antibody deficiency diseases. J Allergy Clin Immunol 2013; 131(4): 1001-1005. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2013.02.028>. Go to original source... Go to PubMed...
    23. Lucas M, Lee M, Lortan J et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010; 125(6): 1354-1360. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2010.02.040>. Go to original source... Go to PubMed...
    24. Kuruvilla M, de la Morena MT. Antibiotic prophylaxis in primary immune deficiency disorders. J Allergy Clin Immunol Pract 2013; 1(6): 573-582. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaip.2013.09.013>. Go to original source... Go to PubMed...
    25. Doubková M, Moulis M, Skřičková J. Intersticiální Plicní procesy a granulomatózy asociované s běžným variabilním imunodeficitem. Vnitř Lék 2015; 61(2): 119-124. Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.